SynAct Pharma has announced that Björn Westberg has been appointed Chief Financial Officer and member of the management team at SynAct.
“I’m excited at the opportunity to join SynAct at such an important time in its development,” says Björn Westberg. “The SynAct team has accomplished a lot over the past several years from joining the main list in Stockholm, gaining new investors and driving its development platform. I look forward to joining the team.”
Björn Westberg has extensive experience from the life science sector, from smaller pharmaceutical companies to contract manufacturing and “Big Pharma”. He served as a CFO of several listed companies and most recently comes from his role as CFO at Attgeno. He has more than 25 years of experience in the life science sector and has served as a chief financial officer since 2001. Prior to his role at privately held Attgeno, he was CFO at global cloud software company Enea, Swedish medtech Bonesupport, both of which are listed on Nasdaq Stockholm, and pharmaceutical developer and manufacturer Recipharm. He started his career at AstraZeneca where he worked in various capacities from 1989-2001.
Björn Westberg will take up the position full-time from August 16. He will formally start his position as CFO part-time on June 15, and replace Patrik Renblad who announced his resignation in February.
Photo of Björn Westberg: SynAct